27805-84-1

Usage

Uses

Used in Flavor and Fragrance Industry:
(Z)-2-Pentenoic acid ethyl ester is used as a flavor and fragrance ingredient for its distinctive fruity, sweet scent. It enhances the sensory experience of food and beverages, contributing to their overall appeal and consumer satisfaction.
Used in Organic Synthesis:
(Z)-2-Pentenoic acid ethyl ester is utilized as a precursor in the synthesis of other organic compounds. Its reactivity and functional groups make it a valuable building block for creating a wide range of chemical products, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in the Food and Beverage Industry:
(Z)-2-Pentenoic acid ethyl ester is used as a flavoring agent in the food and beverage industry to impart a pleasant, fruity aroma and taste to products. Its ability to enhance the sensory profile of various consumables makes it a sought-after ingredient for improving the overall flavor experience.
Used in the Cosmetics and Personal Care Industry:
(Z)-2-Pentenoic acid ethyl ester is employed in the cosmetics and personal care industry as a fragrance component. Its sweet, fruity scent adds a pleasant aroma to products, making them more appealing to consumers and enhancing their sensory attributes.
Used in the Pharmaceutical Industry:
(Z)-2-Pentenoic acid ethyl ester is used in the pharmaceutical industry as an intermediate in the synthesis of various drugs. Its unique chemical properties allow it to be transformed into active pharmaceutical ingredients, contributing to the development of new medications and therapies.

InChI:InChI=1/C7H12O2/c1-3-5-6-7(8)9-4-2/h5-6H,3-4H2,1-2H3/b6-5+

Upstream product

• 27846-50-0 3-Acetoxy-pentanoic acid ethyl ester 
• 72258-75-4 2-<(ethoxycarbonyl)methyl>-2-oxo-4,5-dimethyl-1,3,2-dioxaphospholane 
• 123-38-6 propionaldehyde 
• 16666-42-5 (Z)-2-pentenoic acid 
• 75-03-6 ethyl iodide 
• 4083-85-6 triphenyl(carbethoxymethyl)phosphonium bromide 
• 64-17-5 ethanol 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 108-29-2 5-methyl-dihydro-furan-2-one 
• 55314-57-3 ethyl pent-2-ynoate 

Downstream Products

• 134420-93-2 ethyl 3-(benzylamino)valerate 
• 1428243-70-2 (R)-1-(naphthalen-1-yl)ethanammonium (3S,4R)-1-(benzyloxycarbonyl)-4-ethylpyrrolidine-3-carboxylate 
• 1447673-31-5 (S)-1-(naphthalen-1-yl)ethanammonium (3S,4R)-1-(benzyloxycarbonyl)-4-ethylpyrrolidine-3-carboxylate 
• 1428243-25-7 (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt 
• 1428243-26-8 (3R,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate 
• 1428243-27-9 (3R,4S)-benzyl 3-(2-(tert-butoxycarbonyl(5-tosyl-5H-pyrrolo[2,3-b]pyrazin-2-yl)amino)acetyl)-4-ethylpyrrolidine-1-carboxylate 
• 98587-10-1 (S)-3-n-butyl-5-methylfuran-2(5H)-one 

Relevant academic research and scientific papers

Total Synthesis and Stereochemical Revision of Phacelocarpus 2-Pyrone A

The first total synthesis of phacelocarpus 2-pyrone A is reported. The original natural compound was tentatively assigned (by NMR spectroscopy) as containing two cis-alkenes and a trans-vinyl ether connected to a 2-pyrone ring motif. Our computational pre

Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib

Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.

JAK kinase inhibitor, preparation method thereof, and application in the field of medicines

The application relates to a JAK kinase inhibitor, a preparation method thereof, and an application in the field of medicines and belongs to the field of medical chemistry. In the application, a series of novel small-molecular JAK inhibitors are provided and are represented as the general formula (II). The compounds have better effects and higher safety in prevention or treatment on JAK-related adaptation diseases.

One-step Synthesis of Core-Gold/Shell-Ceria Nanomaterial and Its Catalysis for Highly Selective Semihydrogenation of Alkynes

We report a facile synthesis of new core-Au/shell-CeO2 nanoparticles (Au@CeO2) using a redox-coprecipitation method, where the Au nanoparticles and the nanoporous shell of CeO2 are simultaneously formed in one step. The Au@CeO2 catalyst enables the highly selective semihydrogenation of various alkynes at ambient temperature under additive-free conditions. The core-shell structure plays a crucial role in providing the excellent selectivity for alkenes through the selective dissociation of H2 in a heterolytic manner by maximizing interfacial sites between the core-Au and the shell-CeO2.

JAK1 SELECTIVE INHIBITOR AND USES THEREOF

The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either

NOVEL TRICYCLIC COMPOUNDS

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

A PROCESS FOR THE PREPARATION OF AN ALKYL ALKENOATE

A process for the preparation of an alkyl alkenoate, wherein a lactone of the general molecular formula (I) wherein n is 1, 2 or 3, R1 is a C1-C4 alkyl group, and R2, R3 and R4 are, independently, a H atom or a C1-C4 alkyl group, is reacted with a C1-C4 alkyl alcohol in a liquid phase in the presence of a strong acid catalyst at transesterification conditions to form the alkyl alkenoate, wherein alkyl alkenoate and alcohol are continuously removed from the liquid phase by distillation.

Stereocontrol of the Horner-Wadsworth-Emmons Reaction: Application to the Synthesis of HIV-1 Protease Inhibitors

A systematic study on the Horner-Wadsworth-Emmons (HWE) reaction has shown that ethyl diphenylphosphonoacetate and methyl diphenylphosphonoacetate give a high excess of (Z)-alkenes. These reaction conditions were then used to prepare (Z)-ethyl-5-phenylpent-2-enoate, the corresponding (E)-isomer being prepared by standard Wittig chemistry. Reduction of each allylic ester, with diisobutylaluminium hydride (DIBAL), gave the allylic alcohols (15) and (19), respectively. Epoxidation of (15) and (19), under Sharpless conditions, gave separate samples of all four stereoisomers of 2,3-epoxy-5-phenylpentan-1-ol. Esterification of each isomer with Cbz-valine, under Mitsunobu conditions, provided (9)-(12) which were assayed against HIV protease. The cis series (9)-(10) proved to be significantly more potent than the trans (11)-12) and, within each of these series, the isomers derived from L-diisopropyltartrate [(9) and (11)] were the most active.

GABA-uptake inhibitors: Construction of a general pharmacophore model and successful prediction of a new representative

A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1 μM. This value is as good as those of the best GABA-uptake inhibitors known today.

Stereoselective synthesis of the diunsaturated metabolites of valproic acid

Two diene metabolites of valproic acid (VPA), (E)-2-n-propyl-2,4-pentadienoic acid (1) and (E)-2-(1'-propenyl)-(E)-2-pentenoic acid (2), were stereoselectively synthesized. Mesylate elimination in the final step to produce the unsaturation at position 2 was stereospecific for the (E)-configuration in the case of 2. Gas chromatography-mass spectroscopy and NMR were used to confirm the configuration of each diene including the minor isomers, (Z)-2-n-propyl-2,4-pentadienoic acid (9) and (Z)-2-(1'-propenyl)-(E)-2-pentenoic acid (18). Analysis of the dienes, as PFB derivatives by negative chemical ionization GC-MS from a serum extract of a patient on VPA therapy, revealed the presence of four peaks that in order of elution correspond to 9, 18, 1, and 2.